Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 11/20 | 0.95 |
| ▸ | CA9 | Q16790 | 10/20 | 0.95 |
| ▸ | CA12 | O43570 | 9/20 | 0.95 |
| ▸ | CA1 | P00915 | 8/20 | 0.95 |
| ▸ | CA7 | P43166 | 4/20 | 0.95 |
| ▸ | CA6 | P23280 | 3/20 | 0.95 |
| ▸ | CA5A | P35218 | 3/20 | 0.95 |
| ▸ | CA5B | Q9Y2D0 | 3/20 | 0.95 |
| ▸ | CA3 | P07451 | 2/20 | 0.95 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.62 |
| ▸ | PTGS2 | P35354 | 5/20 | 0.60 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | CA4 | P22748 | 3/20 | 0.58 |
| ▸ | CA13 | Q8N1Q1 | 2/20 | 0.56 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.56 |
| ▸ | USP2 | O75604 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | AGO2 | Q9UKV8 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| P-Toluenesulfonamide SCHEMBL1331323 | 0.97 | CA2 (1.00) | CA2CA9CA12CA1CA7 | |
| P-Toluenesulfonamide SCHEMBL31527821 | 0.97 | CA2 (1.00) | CA2CA9CA12CA1CA7 | |
| P-Toluenesulfonamide SCHEMBL7370 | 0.97 | CA2 (1.00) | CA2CA9CA12CA1CA7 | |
| P-Toluenesulfonamide SCHEMBL9377640 | 0.95 | CA2 (0.95) | CA2CA9CA12CA1CA7 | |
| P-Toluenesulfonamide SCHEMBL8070437 | 0.95 | CA2 (0.95) | CA2CA9CA12CA1CA7 | |
| P-Toluenesulfonamide SCHEMBL8071454 | 0.95 | CA2 (0.95) | CA2CA9CA12CA1CA7 | |
| P-Toluenesulfonamide SCHEMBL357964 | 0.95 | CA2 (0.95) | CA2CA9CA12CA1CA7 | |
| P-Toluenesulfonamide SCHEMBL8376384 | 0.95 | CA2 (0.95) | CA2CA9CA12CA1CA7 | |
| P-Toluenesulfonamide SCHEMBL15401330 | 0.95 | CA2 (0.95) | CA2CA9CA12CA1CA7 | |
| P-Toluenesulfonamide SCHEMBL391243 | 0.95 | CA2 (0.95) | CA2CA9CA12CA1CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0211944-B1 | CARBONATE POLYMER COMPOSITIONS CONTAINING A SALT OF AN AROMATIC SULFONAMIDE AND A FREE AROMATIC SULFIMIDE | THE DOW CHEMICAL COMPANY (US) | 1989-08-16 | — | — | EP | claimed |
| CN-113754509-A | Method for preparing conjugated diene with single stereo configuration from allyl alcohol compound | 中山大学 | 2021-12-07 | — | — | CN | disclosed |
| EP-2484725-B1 | POLYESTER RESIN COMPOSITION, POLYESTER FIBER, POLYESTER RESIN MOLDED ARTICLE, AND PROCESS FOR PRODUCTION OF NUCLEATING AGENT FOR POLYESTER RESIN | ADEKA CORP (JP) | 2017-07-19 | — | — | EP | disclosed |
| US-20140001672-A1 | POLYESTER RESIN COMPOSITION, POLYESTER FIBER, POLYESTER RESIN MOLDED ARTICLE, AND PROCESS FOR PRODUCTION OF NUCLEATING AGENT FOR POLYESTER RESIN | ADEKA CORPORATION (JP) | 2014-01-02 | — | — | US | disclosed |
| EP-1137642-B1 | BIS-SULFONAMIDES | ACTELION PHARMACEUTICALS LTD (CH) | 2007-12-05 | — | — | EP | disclosed |
| CN-1332942-C | Sulfonylamino-acetic acid derivatives and their use as orexin receptor antagonists | ACTELION PHARMACEUTICALS LTD (CH) | 2007-08-22 | — | — | CN | disclosed |
| US-20060079533-A1 | Methods of treating alzheimer's disease | NIEMAN JAMES A | 2006-04-13 | — | — | US | disclosed |
| CN-1703397-A | Sulfonylamino-acetic acid derivatives and their use as orexin receptor antagonists | ACTELION PHARMACEUTICALS LTD (CH) | 2005-11-30 | — | — | CN | disclosed |
| US-6596719-B1 | Manufacturing those compounds, pharmaceutical compositions containing one or more of those compounds as endothelin antagonists, and a method of treating a subject having a disorder involving endothelin with the compounds of the | ACTELIO PHARMACEUTICALS LTD. (CH) | 2003-07-22 | — | — | US | disclosed |
| WO-2002076440-A2 | METHODS OF TREATING ALZHEIMER'S DISEASE WITH PIPERIDIN DERIVATES | ELAN PHARMACEUTICALS, INC. (US) | 2002-10-03 | — | — | WO | disclosed |
| WO-2001017976-A1 | BIS-SULFONAMIDES | ACTELION PHARMACEUTICALS LTD (CH) | 2001-03-15 | — | — | WO | disclosed |
| US-6150526-A | Piperidine derivative having renin inhibiting activity | HOFFMANN-LA ROCHE INC. (US) | 2000-11-21 | — | — | US | disclosed |
| US-6051712-A | PREVENTION OF HIGH BLOOD PRESSURE AND CARDIAC INSUFFICIENCY, AS WELL AS GLAUCOMA, CARDIAC INFARCT, KIDNEY INSUFFICIENCY AND RESTENOSIS | HOFFMANN-LA ROCHE INC. (US) | 2000-04-18 | — | — | US | disclosed |
| US-5270313-A | Treatment of circulatory disorders | HOFFMANN-LA ROCHE INC. (US) | 1993-12-14 | — | — | US | disclosed |
| EP-0211944-B1 | CARBONATE POLYMER COMPOSITIONS CONTAINING A SALT OF AN AROMATIC SULFONAMIDE AND A FREE AROMATIC SULFIMIDE | THE DOW CHEMICAL COMPANY (US) | 1989-08-16 | — | — | EP | disclosed |
| US-4300897-A | SAFE FOR DYED FABRICS; ALSO CONTAINS AN AROMATIC SULFONAMIDE | COLGATE-PALMOLIVE COMPANY (US) | 1981-11-17 | — | — | US | disclosed |
| US-4183955-A | Troponyl-oxamic acid derivatives for treating allergic conditions | Ayerst. McKenna & Harrison Limited (CA) | 1980-01-15 | — | — | US | disclosed |
| US-4125625-A | ANTIALLERGENS | AYERST, MCKENNA & HARRISON LIMITED (CA) | 1978-11-14 | — | — | US | disclosed |
| US-4123376-A | AROMATIC SULFONAMIDE | COLGATE-PALMOLIVE COMPANY (US) | 1978-10-31 | — | — | US | disclosed |
| US-4057556-A | ANTIALLERGENS | AYERST, MCKENNA & HARRISON LTD. (CA) | 1977-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060079533-A1 | Methods of treating alzheimer's disease | BACE1, PSEN1, PSEN2 | CA2 1585/4885CA9 3420/4885CA12 2820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.